MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
MAIA Biotechnology reports that 150 patients have been treated with ateganosine sequenced with a checkpoint inhibitor across its ongoing THIO-101 Phase 2 and THIO-104 Phase 3 trials. Part C of THIO-101 is fully enrolled, THIO-104 has 65 patients enrolled toward a 100-patient year-end target, and the company cites a 90.5% interim disease control rate for the combination in an efficacy-evaluable population.